{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:32:28Z","timestamp":1782790348225,"version":"3.54.5"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The combination of polatuzumab, bendamustine and rituximab (pola+BR) was authorized for the treatment of relapsed or refractory Diffuse large B cell lymphoma (DLBCL). This study used the FDA database to identify safety signals related to the treatment protocol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The adverse events (AEs) from 2019Q1 to 2023Q3 were analyzed by calculating the reporting odds ratio. Severe and non-severe cases were compared using either an independent samples t-test or chi-squared (\u03c7<jats:sup>2<\/jats:sup>) test. Additionally, a score sheet was employed to prioritize the signals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In all database, 58 significant signals were detected within 1,597 patients accepting the treatment protocol. Common AEs like neutropenia, thrombocytopenia, and peripheral neuropathy, as well as other AEs like anaemia, sepsis, cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS) were a major focus. In addtion, 51.7%, 45.6% and 1.7% were sorted into low, moderate and high priority in term of clinical importance, respectively. Unexpected significant signals included intestinal obstruction, epilepsy, deep vein thrombosis, haemorrhage, increased blood lactate dehydrogenase and hypercalcemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study identified significant AE signals for pola+BR through realworld disproportionality analysis data and analyzed the severity and clinical priority of these signals, which can assist clinicians in managing related AEs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1459067","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T06:52:29Z","timestamp":1739861549000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database"],"prefix":"10.3389","volume":"16","author":[{"given":"Fang","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xihui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runyan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e798","DOI":"10.1097\/hs9.0000000000000798","article-title":"Real-world outcomes of relapsed\/refractory diffuse large B-cell lymphoma treated with polatuzumab vedotin-based therapy","volume":"6","author":"Argnani","year":"2022","journal-title":"Hemasphere"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1111\/epi.14550","article-title":"Activation of the innate immune system is evident throughout epileptogenesis and is associated with blood-brain barrier dysfunction and seizure progression","volume":"59","author":"Broekaart","year":"2018","journal-title":"Epilepsia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00277-022-05052-x","article-title":"Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey","volume":"102","author":"Dal","year":"2023","journal-title":"Ann. Hematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s40265-019-01175-0","article-title":"Polatuzumab vedotin: first global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e891","DOI":"10.1016\/s2352-3026(21)00311-2","article-title":"Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b\/2 study","volume":"8","author":"Diefenbach","year":"2021","journal-title":"Lancet Haematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/2047487320915663","article-title":"Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system","volume":"28","author":"Gatti","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/psp4.12850","article-title":"Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and\/or metastatic solid tumors","volume":"11","author":"Gibiansky","year":"2022","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e1576","DOI":"10.1002\/wsbm.1576","article-title":"Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment","volume":"14","author":"Gu","year":"2022","journal-title":"WIREs Mech. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"849758","DOI":"10.3389\/fphar.2022.849758","article-title":"Neurological adverse events associated with esketamine: a disproportionality analysis for signal detection leveraging the FDA adverse event reporting system","volume":"13","author":"Guo","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000098706","article-title":"Reversible posterior leukoencephalopathy syndrome after treatment of diffuse large B-cell lymphoma","volume":"30","author":"Haefner","year":"2007","journal-title":"Onkologie"},{"key":"B12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00277-009-0783-x","article-title":"Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma","volume":"89","author":"Hosoi","year":"2010","journal-title":"Ann. Hematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0167722","DOI":"10.1128\/spectrum.01677-22","article-title":"Chemotherapeutic drugs induce different gut microbiota disorder pattern and NOD\/RIP2\/NF-\u03baB signaling pathway activation that lead to different degrees of intestinal injury","volume":"10","author":"Huang","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e24988","DOI":"10.7759\/cureus.24988","article-title":"Posterior reversible encephalopathy syndrome secondary to R-CHOP chemotherapy regimen","volume":"14","author":"Jennane","year":"2022","journal-title":"Cureus"},{"key":"B15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13613-024-01282-6","article-title":"The chain of survival and rehabilitation for sepsis: concepts and proposals for healthcare trajectory optimization","volume":"14","author":"Jouffroy","year":"2024","journal-title":"Ann. Intensive Care"},{"key":"B16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12883-019-1416-1","article-title":"Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report","volume":"19","author":"Kamo","year":"2019","journal-title":"BMC Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/cc11304","article-title":"Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective","volume":"16","author":"Kasi","year":"2012","journal-title":"Crit. Care"},{"key":"B18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s13054-019-2663-7","article-title":"The SOFA score-development, utility and challenges of accurate assessment in clinical trials","volume":"23","author":"Lambden","year":"2019","journal-title":"Crit. Care"},{"key":"B19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/psp4.12192","article-title":"Time-to-Event analysis of polatuzumab vedotin-induced peripheral neuropathy to assist in the comparison of clinical dosing regimens","volume":"6","author":"Lu","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1182\/bloodadvances.2022009145","article-title":"Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas","volume":"7","author":"Lynch","year":"2023","journal-title":"Blood Adv."},{"key":"B21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.euf.2022.07.003","article-title":"Adverse events of axitinib plus pembrolizumab versus lenvatinib plus pembrolizumab: a pharmacovigilance study in Food and drug administration adverse event reporting system","volume":"9","author":"Matsumoto","year":"2023","journal-title":"Eur. Urol. Focus"},{"key":"B22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief. Bioinform"},{"key":"B24","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/s1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.3399\/bjgp20X709349","article-title":"Implementation of the National Early Warning Score in patients with suspicion of sepsis: evaluation of a system-wide quality improvement project","volume":"70","author":"Pullyblank","year":"2020","journal-title":"Br. J. Gen. Pract."},{"key":"B26","doi-asserted-by":"publisher","first-page":"102189","DOI":"10.1016\/j.ctrv.2021.102189","article-title":"Neurological complications of cancer immunotherapy","volume":"97","author":"Roth","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv."},{"key":"B28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"996179","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system","volume":"10","author":"Shu","year":"2022","journal-title":"Front. Public Health"},{"key":"B30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.clml.2020.12.013","article-title":"Polatuzumab vedotin for relapsed\/refractory aggressive B-cell lymphoma: a multicenter post-marketing analysis","volume":"21","author":"Smith","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B31","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/s1470-2045(19)30091-9","article-title":"Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study","volume":"20","author":"Tilly","year":"2019","journal-title":"Lancet Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2147\/ott.S326632","article-title":"Diffuse large B-cell lymphoma (DLBCL): early patient management and emerging treatment options","volume":"15","author":"Vodicka","year":"2022","journal-title":"Onco Targets Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00277-021-04711-9","article-title":"Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience","volume":"101","author":"Wang","year":"2022","journal-title":"Ann. Hematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"967017","DOI":"10.3389\/fphar.2022.967017","article-title":"Do antibody-drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study","volume":"13","author":"Xia","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/cpt.2096","article-title":"Population pharmacokinetics of trastuzumab deruxtecan in patients with HER2-positive breast cancer and other solid tumors","volume":"109","author":"Yin","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN Guidelines\u00ae insights: B-cell lymphomas, version 6.2023","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B39","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/bcp.15494","article-title":"Ocular disorders associated with PCSK9 inhibitors: a pharmacovigilance disproportionality analysis","volume":"89","author":"Zhao","year":"2023","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1459067\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T06:52:32Z","timestamp":1739861552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1459067\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":39,"alternative-id":["10.3389\/fphar.2025.1459067"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1459067","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"article-number":"1459067"}}